Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies publication / By David Žihala
CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma publication / By David Žihala
Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics publication / By David Žihala
Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma publication / By David Žihala
Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma publication / By David Žihala
Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy publication / By David Žihala
NK92 Expressing Anti-BCMA CAR and Secreted TRAIL for the Treatment of Multiple Myeloma: Preliminary In Vitro Assessment publication / By David Žihala
Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility publication / By David Žihala
Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy publication / By David Žihala
